Superbugs, govt subsidies draw big pharma back to antibiotics
Until the past few years, firms had largely given up on new antibiotics
Sydney
BIG pharma is creeping back into development of new antibiotics after decades of largely ignoring the business due to the scant rewards offered by such medications.
With the planet on the brink of losing its miracle cures for bacterial diseases, research incentives from governments are spurring drugmakers to renew efforts to fight antimicrobial resistance and replenish the arsenal of infection-fighting drugs. Giants such as Roche Holding AG and Merck & Co are stepping up their efforts in the field while a host of startups seek partners to help market new products.
"Some large pharmaceutical companies are re-entering the space, and new companies focused on antibacterial development are emerging as industry darlings," said Ankit Mahadevia, chief executive officer of Sper…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Sony deal for Paramount would draw added regulatory scrutiny
Lululemon to shutter Washington distribution center, lay off 128 employees
Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom